Hepatitis A vaccines and the elderly

Travel Medicine and Infectious Disease

Volumn 4, Issue 6, 2006, Pages 303-312

  Genton, Blaise ^a   D'Acremont, Valérie ^a   Furrer, Hans Jacob ^b   Hatz, Christoph ^c   Louis Loutan, ^d  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Elderly; Hepatitis A; Immunogenicity; Seroprotection; Travel; Vaccine

Indexed keywords

HEPATITIS A HEPATITIS B VACCINE; HEPATITIS A VACCINE; HEPATITIS ANTIBODY; HEPATITIS B VACCINE;

ACTIVE IMMUNIZATION; ARTICLE; DOSE RESPONSE; DRUG EFFICACY; ELDERLY CARE; ENDEMIC DISEASE; HEPATITIS A; HEPATITIS A VIRUS; HUMAN; IMMUNE RESPONSE; INDUSTRIALIZATION; INFECTION SENSITIVITY; INNATE IMMUNITY; MORBIDITY; MORTALITY; PRIORITY JOURNAL; SEROPREVALENCE; SINGLE DRUG DOSE; TRAVEL; VACCINATION;

AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; HEPATITIS A; HEPATITIS A VACCINES; HUMANS; IMMUNIZATION, SECONDARY; TRAVEL; VACCINATION;

EID: 33751088004     PISSN: 14778939     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tmaid.2005.10.002     Document Type: Article

References (45)

1. Koff R.S. Hepatitis A. Lancet 351 (1998) 1643-1649
2. Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 48 RR-12 (1999) 1-37
3. Brown G.R., and Persley K. Hepatitis A epidemic in the elderly. South Med J 95 (2002) 826-833
4. Crowcroft N.S., Walsh B., Davison K.L., and Gungabissoon U. Guidelines for the control of hepatitis A virus infection. Community Dis Public Health 4 (2001) 213-227
5. Willner I.R., Uhl M.D., Howard S.C., Williams E.Q., Riely C.A., and Waters B. Serious hepatitis A: an analysis of patients hospitalized during an urban epidemic in the United States. Ann Intern Med 128 (1998) 111-114
6. Studer S., Joller-Jemelka H.I., Steffen R., and Grob P.J. Prevalence of hepatitis A antibodies in Swiss travellers. Eur J Epidemiol 9 (1993) 50-54
7. Morris-Cunnigton M.C., Edmunds W.J., Miller E., and Brown D.W. A population-based seroprevalence study of hepatitis A virus using oral fluid in England and Wales. Am J Epidemiol 159 (2004) 786-794
8. Scoville S.L., Bryan J.P., Tribble D., Paparello S.F., Malone J.L., Ohl C.A., et al. Epidemiology, preventive services, and illnesses of international travelers. Mil Med 162 (1997) 172-178
9. Hill D.R. Health problems in a large cohort of Americans traveling to developing countries. J Travel Med 7 5 (2000) 259-266
10. Steffen R., and Connor B.A. Vaccines in travel health: from risk assessment to priorities. J Travel Med 12 (2005) 26-35
11. Zuckerman J.N., and Powell L. Hepatitis A antibodies in attenders of London travel clinics: cost-benefit of screening prior to hepatitis A immunisation. J Med Virol 44 (1994) 393-394
12. Landry P., and Darioli R. Use of three recommended criteria for anti-hepatitis A antibody testing in travellers. Schweiz Med Wschr 128 (1998) 581-585
13. Bayas J.M., González A., Vilella A., San Martín M., Bertran M.J., and Adell C. Cost analysis of two strategies for preventing hepatitis A virus infection in Spanish travellers to developing countries. Epidemiol Infect 127 (2001) 347-351
14. Fishbain J.T., Eckart R.E., Harner K.C., and Hospenthal D.R. Empiric immunization versus serologic screening: developing a cost-effective strategy for the use of hepatitis A immunizatiuon in travelers. J Travel Med 9 (2002) 71-75
15. WHO. Hepatitis A vaccines-WHO position paper. Weekly Epidemiol Rec 75 (2000) 38-44
16. Leder K., Weller P.F., and Wilson M.E. Travel vaccines and elderly persons: review of vaccines available in the United States. Clin Infect Dis 33 (2001) 1553-1566
17. Franceschi C., Monti D., Sansoni P., and Cossarizza A. The immunology of exceptional individuals: the lesson of centenarians. Immunol Today 16 (1995) 12-16
18. Ben Yehuda A., and Weksler M.E. Immune senescence: mechanisms and clinical implications. Cancer Invest 10 (1992) 525-531
19. Paganelli R., Scala E., Quinti I., and Ansotegui I.J. Humoral immunity in aging. Aging (Milano) 6 (1994) 143-150
20. Wood R.C., MacDonald K.L., White K.E., Hedberg C.W., Hanson M., and Osterholm M.T. Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers. JAMA 270 (1993) 2935-2939
21. Grubeck-Loebenstein B. Changes in the aging immune system. Biologicals 25 (1997) 205-208
22. Rendi-Wagner P., Kundi M., Stemberger H., Wiedermann G., Holzmann H., Hofer M., et al. Antibody-response to three recombinant hepatitis B vaccines: comparative evaluation of multicenter travel-clinic based experience. Vaccine 19 (2001) 2055-2060
23. Smith T.P., Kennedy S.L., and Fleshner M. Influence of age and physical activity on the primary in vivo antibody and T cell-mediated response in men. J Appl Physiol 97 (2004) 491-498
24. ®) in the elderly. J Travel Med, in press.
25. ®) in adults. Vaccine 19 (2001) 4710-4719
26. Scheifele D.W., and Bjornson G.J. Evaluation of inactivated hepatitis A vaccine in Canadians 40 years of age or more. CMAJ 148 (1993) 551-555
27. Tong M.J., Co R.L., and Bellak C. Hepatitis A vaccination. West J Med 158 (1993) 602-605
28. Wagner G., Lavanchy D., Darioli R., Pecoud A., Brulein V., Safary A., et al. Simultaneous active and passive immunization against hepatitis A studied in a population of travelers. Vaccine 11 (1993) 1027-1032
29. Briem H., and Safary A. Immunogenicity and safety in adults of hepatitis A virus vaccine administered as a single dose with a booster 6 months later. J Med Virol 44 (1994) 443-445
30. McMahon B.J., Williams J., Bulkow L., Snowball M., Wainwright R., Kennedy M., et al. Immunogenicity of an inactivated hepatitis A vaccine in Alaska Native children and Native and non-Native adults. J Infect Dis 171 (1995) 676-679
31. Chen X.Q., Bulbul M., de Gast G.C., van Loon A.M., Nalin D.R., and van Hattum J. Immunogenicity of two versus three injections of inactivated hepatitis A vaccine in adults. J Hepatol 26 2 (1997) 260-264
32. Hopperus Buma A.P., van Doornum G.J., Veltink R.L., van Ameijden E.J., Leentvaar-Kuijpers A., and Coutinho R.A. Immunogenicity of an inactivated hepatitis A vaccine in Dutch United Nations troops. Vaccine 15 12-13 (1997) 1413-1417
33. Reuman P.D., Kubilis P., Hurni W., Brown L., and Nalin D. The effect of age and weight on the response to formalin inactivated, alum-adjuvanted hepatitis A vaccine in healthy adults. Vaccine 15 (1997) 1157-1161
34. Wolters B., Junge U., Dziuba S., and Roggendorf M. Immunogenicity of combined hepatitis A and B vaccine in elderly persons. Vaccine 21 25-26 (2003) 3623-3628
35. Stoffel M., Lievens M., Dieussaert I., Martin I., and Andre F. Immunogenicity of Twinrix in older adults: a critical analysis. Expert Rev Vaccines 2 (2003) 9-14
36. Nothdurft H.D., Aumüller H., Aumüller R., Dames W., Stamer K., Kroetzsch H., et al. [Letter to the editor]. Vaccine 22 (2004) 592-593
37. Van Damme P., Van Herck K., and Van der W.M. Combined hepatitis A and B vaccine in elderly. Vaccine 22 (2004) 303-304
38. Wiedermann G. Hepatitis A+B vaccine in elderly persons. J Travel Med 11 (2004) 130-132
39. Nalin D.R., Kuter B.J., Brown L., Patterson C., Calandra G.B., Werzberger A., et al. Worldwide experience with the CR326F-derived inactivated hepatitis A virus vaccine in pediatric and adult populations: an overview. J Hepatol 18 Suppl 2 (1993) S51-S55
40. Shaw Jr. F.E., Guess H.A., Roets J.M., Mohr F.E., Coleman P.J., Mandel E.J., et al. Effect of anatomic injection site, age and smoking on the immune response to hepatitis B vaccination. Vaccine 7 (1989) 425-430
41. Assad S., and Francis A. Over a decade of experience with a yeast recombinant hepatitis B vaccine. Vaccine 18 (1999) 57-67
42. Goilav C., Zuckerman J., Lafrenz M., Vidor E., Lauwers S., Ratheau C., et al. Immunogenicity and safety of a new inactivated hepatitis A vaccine in a comparative study. J Med Virol 46 (1995) 287-292
43. Propst T., Propst A., Lhotta K., Vogel W., and König P. Reinforced intradermal hepatitis B vaccination in hemodialysis patients is superior in antibody response to intramuscular or subcutaneous vaccination. Am J Kidney Dis 32 (1998) 1041-1045
44. Keeffe E.B., Iwarson S., McMahon B.J., Lindsay K.L., Koff R.S., Manns M., et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology 27 (1998) 881-886
45. Toovey S., Jamieson A., and Holloway M. Travelers' knowledge, attitudes and practices on the prevention of infectious diseases: results from a study at Johannesburg International Airport. J Travel Med 11 (2004) 16-22